Asia-Pacific Generics Market Summary, Competitive Analysis and Forecast, 2017-2026
July 6, 2022
MarketLine
46
PDF
Asia-Pacific Generics Market Summary, Competitive Analysis and Forecast, 2017-2026
Abstract
Summary
Generics in Asia-Pacific industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2017-21, and forecast to 2026). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. - The Asia-Pacific generics market had total revenues of $148.9bn in 2021, representing a compound annual growth rate (CAGR) of 6% between 2016 and 2021. - Market consumption volume increased with a CAGR of 2.2% between 2016 and 2021, to reach a total of 86.1 % in 2021. - Growth in the market was primarily driven by growth in China and India. In the Chinese market, an aging population alongside increased awareness over healthcare has led to strong growth for generics.
Scope
- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Asia-Pacific - Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Asia-Pacific - Leading company profiles reveal details of key generics market players’ global operations and financial performance - Add weight to presentations and pitches by understanding the future growth prospects of the Asia-Pacific generics market with five year forecasts by both value and volume
Reasons to Buy
- What was the size of the Asia-Pacific generics market by value in 2021? - What will be the size of the Asia-Pacific generics market in 2026? - What factors are affecting the strength of competition in the Asia-Pacific generics market? - How has the market performed over the last five years? - What are the main segments that make up Asia-Pacific's generics market?
Content
Table of Contents 1 Executive Summary 1.1. Market value 1.2. Market value forecast 1.3. Market volume 1.4. Market volume forecast 1.5. Geography segmentation 1.6. Market rivalry 1.7. Competitive Landscape 2 Market Overview 2.1. Market definition 2.2. Market analysis 3 Market Data 3.1. Market value 3.2. Market volume 4 Market Segmentation 4.1. Geography segmentation 5 Market Outlook 5.1. Market value forecast 5.2. Market volume forecast 6 Five Forces Analysis 6.1. Summary 6.2. Buyer power 6.3. Supplier power 6.4. New entrants 6.5. Threat of substitutes 6.6. Degree of rivalry 7 Competitive Landscape 7.1. Who are the leading players? 7.2. What are the strengths/weaknesses of the leading players? 7.3. Has there been any significant recent M&A activity? 7.4. How did the COVID-19 pandemic impact leading players? 8 Company Profiles 8.1. Teva Pharmaceutical Industries Limited 8.2. Viatris Inc. 8.3. Sun Pharmaceutical Industries Ltd 8.4. Pfizer Inc. 9 Macroeconomic Indicators 9.1. Country data 10 Appendix 10.1. Methodology 10.2. Industry associations 10.3. Related MarketLine research 10.4. About MarketLine
List of Figures Figure 1: Asia-Pacific generics market value: $ billion, 2016-21 Figure 2: Asia-Pacific generics market volume: %, 2016-21 Figure 3: Asia-Pacific generics market geography segmentation: % share, by value, 2021 Figure 4: Asia-Pacific generics market value forecast: $ billion, 2021-26 Figure 5: Asia-Pacific generics market volume forecast: %, 2021-26 Figure 6: Forces driving competition in the generics market in Asia-Pacific, 2021 Figure 7: Drivers of buyer power in the generics market in Asia-Pacific, 2021 Figure 8: Drivers of supplier power in the generics market in Asia-Pacific, 2021 Figure 9: Factors influencing the likelihood of new entrants in the generics market in Asia-Pacific, 2021 Figure 10: Factors influencing the threat of substitutes in the generics market in Asia-Pacific, 2021 Figure 11: Drivers of degree of rivalry in the generics market in Asia-Pacific, 2021
Generics in Asia-Pacific industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2017-21, and forecast to 2026). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. - The Asia-Pacific generics market had total revenues of $148.9bn in 2021, representing a compound annual growth rate (CAGR) of 6% between 2016 and 2021. - Market consumption volume increased with a CAGR of 2.2% between 2016 and 2021, to reach a total of 86.1 % in 2021. - Growth in the market was primarily driven by growth in China and India. In the Chinese market, an aging population alongside increased awareness over healthcare has led to strong growth for generics.
Scope
- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Asia-Pacific - Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Asia-Pacific - Leading company profiles reveal details of key generics market players’ global operations and financial performance - Add weight to presentations and pitches by understanding the future growth prospects of the Asia-Pacific generics market with five year forecasts by both value and volume
Reasons to Buy
- What was the size of the Asia-Pacific generics market by value in 2021? - What will be the size of the Asia-Pacific generics market in 2026? - What factors are affecting the strength of competition in the Asia-Pacific generics market? - How has the market performed over the last five years? - What are the main segments that make up Asia-Pacific's generics market?
Table of Contents 1 Executive Summary 1.1. Market value 1.2. Market value forecast 1.3. Market volume 1.4. Market volume forecast 1.5. Geography segmentation 1.6. Market rivalry 1.7. Competitive Landscape 2 Market Overview 2.1. Market definition 2.2. Market analysis 3 Market Data 3.1. Market value 3.2. Market volume 4 Market Segmentation 4.1. Geography segmentation 5 Market Outlook 5.1. Market value forecast 5.2. Market volume forecast 6 Five Forces Analysis 6.1. Summary 6.2. Buyer power 6.3. Supplier power 6.4. New entrants 6.5. Threat of substitutes 6.6. Degree of rivalry 7 Competitive Landscape 7.1. Who are the leading players? 7.2. What are the strengths/weaknesses of the leading players? 7.3. Has there been any significant recent M&A activity? 7.4. How did the COVID-19 pandemic impact leading players? 8 Company Profiles 8.1. Teva Pharmaceutical Industries Limited 8.2. Viatris Inc. 8.3. Sun Pharmaceutical Industries Ltd 8.4. Pfizer Inc. 9 Macroeconomic Indicators 9.1. Country data 10 Appendix 10.1. Methodology 10.2. Industry associations 10.3. Related MarketLine research 10.4. About MarketLine
List of Figures Figure 1: Asia-Pacific generics market value: $ billion, 2016-21 Figure 2: Asia-Pacific generics market volume: %, 2016-21 Figure 3: Asia-Pacific generics market geography segmentation: % share, by value, 2021 Figure 4: Asia-Pacific generics market value forecast: $ billion, 2021-26 Figure 5: Asia-Pacific generics market volume forecast: %, 2021-26 Figure 6: Forces driving competition in the generics market in Asia-Pacific, 2021 Figure 7: Drivers of buyer power in the generics market in Asia-Pacific, 2021 Figure 8: Drivers of supplier power in the generics market in Asia-Pacific, 2021 Figure 9: Factors influencing the likelihood of new entrants in the generics market in Asia-Pacific, 2021 Figure 10: Factors influencing the threat of substitutes in the generics market in Asia-Pacific, 2021 Figure 11: Drivers of degree of rivalry in the generics market in Asia-Pacific, 2021